Two big themes are set to dominate this year. The first is safety. The FDA’s investigation of T-cell malignancies associated with CAR-T products approved for blood cancers may make these treatments less appealing. However, many patients with autoimmune diseases and cancer already accept some risk of secondary malignancies, so this isn’t necessarily going to derail the whole CAR-T space. We can expect plenty of discussion of the likely impact of the news in the panel sessions – and the network
关注微信
